FNCH (Finch Therapeutics Group) Total Assets : $45.58 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Finch Therapeutics Group Total Assets?

Finch Therapeutics Group's Total Assets for the quarter that ended in Jun. 2024 was $45.58 Mil.

During the past 12 months, Finch Therapeutics Group's average Total Assets Growth Rate was -10.00% per year. During the past 3 years, the average Total Assets Growth Rate was -22.80% per year.

During the past 5 years, Finch Therapeutics Group's highest 3-Year average Total Assets Growth Rate was 14.40%. The lowest was -22.80%. And the median was -4.20%.

Total Assets is connected with ROA %. Finch Therapeutics Group's annualized ROA % for the quarter that ended in Jun. 2024 was -40.42%. Total Assets is also linked to Revenue through Asset Turnover. Finch Therapeutics Group's Asset Turnover for the quarter that ended in Jun. 2024 was 0.00.

Finch Therapeutics Group Total Assets Historical Data

The historical data trend for Finch Therapeutics Group's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Finch Therapeutics Group Total Assets Chart

Finch Therapeutics Group Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

103.57

165.34

225.37

162.94

55.37

Finch Therapeutics Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Assets	Get a 7-Day Free Trial														66.86	59.49	55.37	50.09	45.58

Finch Therapeutics Group Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Finch Therapeutics Group's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	22.886	+	32.487
	=	55.37

Finch Therapeutics Group's Total Assets for the quarter that ended in Jun. 2024 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2024 )	+	Total Liabilities (Q: Jun. 2024 )
	=	14.219	+	31.357
	=	45.58

Finch Therapeutics Group (OTCPK:FNCH) Total Assets Explanation

Total Assets is connected with ROA %.

Finch Therapeutics Group's annualized ROA % for the quarter that ended in Jun. 2024 is

ROA %	=	Net Income (Q: Jun. 2024 )	/	( (Total Assets (Q: Mar. 2024 )	+	Total Assets (Q: Jun. 2024 ))	/ count )
	=	-19.336	/	( (50.092	+	45.576)	/ 2 )
	=	-19.336	/	47.834
	=	-40.42 %

Note: The Net Income data used here is four times the quarterly (Jun. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Finch Therapeutics Group's Asset Turnover for the quarter that ended in Jun. 2024 is

	Asset Turnover
=	Revenue (Q: Jun. 2024 )	/	( (Total Assets (Q: Mar. 2024 )	+	Total Assets (Q: Jun. 2024 ))	/ count )
=	0	/	( (50.092	+	45.576)	/ 2 )
=	0	/	47.834
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Finch Therapeutics Group Total Assets Related Terms

Thank you for viewing the detailed overview of Finch Therapeutics Group's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Finch Therapeutics Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Finch Therapeutics Group Inc (OTCPK:FNCH) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 State Street, Suite 100, Boston, MA, USA, 02109

Website

https://www.finchtherapeutics.com

Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).

Executives

Jeffery A Smisek	director	1600 SMITH STREET, HQSEO, HOUSTON TX 77002
Susan E Graf	director	400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Lance E Thibault	officer: Chief Financial Officer
Matthew P. Blischak	officer: Chief Executive Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SOMERVILLE MA 02143
Joseph Vittiglio	officer: Chief Business & Legal Officer	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Marc Blaustein	officer: Chief Operating Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Domenic J Ferrante	director	BROOKSIDE CAPITAL MANAGEMENT LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Samuel A Hamood	director	C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Joanne L. Viney	director	C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Nicholas Haft	director	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Christian H. Lange	director	28 HAVEMEYER PLACE, GREENWICH CT 06830
Crestovo Investor Llc	director, 10 percent owner	28 HAVEMEYER PLACE, GREENWICH CT 06830
Gregory D Perry	officer: Chief Financial Officer	C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Chris Shumway	director, 10 percent owner	28 HAVEMEYER PLACE, GREENWICH CT 06830
Zain Kassam	officer: Chief Medical Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143